Global Bio Investor Sells Over 500,000 Shares of CF Drug Development Company

From April 14 to 16, global healthcare investor Ovid Med Advisors sold approximately 510,000 shares of common stock in Sionna Therapeutics, Inc. (SION) on the open market under a Rule 10b5-1 trading plan. The shares traded at prices ranging from $44.51 to $45.34 per share, generating total proceeds of about $23 million (roughly KRW 31 billion). As a result, Ovid Med’s indirect holding in Sionna fell from around 3.48 million shares to approximately 3.02 million shares.

Ovid Med Advisors has stated that it recognizes beneficial ownership only to the extent of its financial interest, and one of its designated representatives currently serves on Sionna’s board of directors.

On April 7, Sionna announced its participation in the Raymond James 2026 Biotech Innovation Symposium. In March, the company also disclosed that its chief legal officer, JP Morgan and other key stakeholders had reduced their stakes.

Founded in 2019, Sionna is a clinical-stage biotech company developing small-molecule drugs targeting the NBD1 domain of the CFTR protein to treat cystic fibrosis. The company raised funds for its pipeline through a Nasdaq listing in 2025.